A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. (2019)
Attributed to:
Stratified Medicine to Optimise Treatment for Hepatitis C Virus Infection
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jval.2018.12.011
PubMed Identifier: 31198187
Publication URI: http://europepmc.org/abstract/MED/31198187
Type: Journal Article/Review
Volume: 22
Parent Publication: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Issue: 6
ISSN: 1098-3015